Cargando…

Long COVID in France: prevalence, management and long-term impact: Tatjana Makovski

 : Certain percentage of population experiences persistent symptoms months after an acute Covid-19 episode (Long-COVID), with a significant impact on daily-life. Few studies exist on its prevalence and its impact among the general population. The main objective of this survey was to estimate the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Makovski, TT, Decio, V, Carcaillon-Bentata, L, Alleaume, C, Beltzer, N, Robineau, O, Gallay, A, Tebeka, S, Coste, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593843/
http://dx.doi.org/10.1093/eurpub/ckac129.282
_version_ 1784815262992695296
author Makovski, TT
Decio, V
Carcaillon-Bentata, L
Alleaume, C
Beltzer, N
Robineau, O
Gallay, A
Tebeka, S
Coste, J
author_facet Makovski, TT
Decio, V
Carcaillon-Bentata, L
Alleaume, C
Beltzer, N
Robineau, O
Gallay, A
Tebeka, S
Coste, J
author_sort Makovski, TT
collection PubMed
description  : Certain percentage of population experiences persistent symptoms months after an acute Covid-19 episode (Long-COVID), with a significant impact on daily-life. Few studies exist on its prevalence and its impact among the general population. The main objective of this survey was to estimate the prevalence of Long COVID among the general adult population in France. Secondary objectives were to evaluate Long COVID management and to assess impact of this clinical condition on quality of life and mental health. Cross-sectional study was performed in March-April 2022 using an online self-administered questionnaire. The sample was selected by the quota method from a panel of volunteers. Its representativeness was ensured by appropriate weighting. Three groups were described: Long-COVID, COVID without persistent symptoms, never COVID. Post COVID-19 condition as defined by the WHO was applied for prevalence estimation. The prevalence was calculated by age and sex. Health care consumption and impact of Long COVID on quality of life and mental health will be studied comparing the three groups, using weighted adjusted polytomic regressions. Here, we present preliminary findings on Long COVID prevalence. There were 27,537 respondents, 52% females, mean age (SD) 49 (±16.5). Confirmed or probable COVID-19 was reported by 33.9% of participants; of whom 85.1% had confirmed laboratory test. Majority (65.1%) had COVID-19 <3 months ago. Long COVID concerned 1,086 (4%) participants. Prevalence was higher for females 4.6% vs. 3.3% for males, and among younger population for both sex groups. Overall, prevalence of Long COVID by age group was: 18-34 (6%), 35-49 (4.7%), 50-64 (3.4%), ≥65 (1.8%). This is a first estimation of Long COVID prevalence among the French population. Representativeness of the sample should be interpreted with caution due to a sample based on volunteers’ response. Ongoing analyses will provide clearer understanding of the impact of Long COVID. KEY MESSAGES: • This is a first estimation of Long COVID prevalence among the French population. • There is a significant portion of the French population impacted by persisting or reoccurring symptoms defined by Long COVID; its impact and care management will be further evaluated.
format Online
Article
Text
id pubmed-9593843
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95938432022-11-04 Long COVID in France: prevalence, management and long-term impact: Tatjana Makovski Makovski, TT Decio, V Carcaillon-Bentata, L Alleaume, C Beltzer, N Robineau, O Gallay, A Tebeka, S Coste, J Eur J Public Health Parallel Programme  : Certain percentage of population experiences persistent symptoms months after an acute Covid-19 episode (Long-COVID), with a significant impact on daily-life. Few studies exist on its prevalence and its impact among the general population. The main objective of this survey was to estimate the prevalence of Long COVID among the general adult population in France. Secondary objectives were to evaluate Long COVID management and to assess impact of this clinical condition on quality of life and mental health. Cross-sectional study was performed in March-April 2022 using an online self-administered questionnaire. The sample was selected by the quota method from a panel of volunteers. Its representativeness was ensured by appropriate weighting. Three groups were described: Long-COVID, COVID without persistent symptoms, never COVID. Post COVID-19 condition as defined by the WHO was applied for prevalence estimation. The prevalence was calculated by age and sex. Health care consumption and impact of Long COVID on quality of life and mental health will be studied comparing the three groups, using weighted adjusted polytomic regressions. Here, we present preliminary findings on Long COVID prevalence. There were 27,537 respondents, 52% females, mean age (SD) 49 (±16.5). Confirmed or probable COVID-19 was reported by 33.9% of participants; of whom 85.1% had confirmed laboratory test. Majority (65.1%) had COVID-19 <3 months ago. Long COVID concerned 1,086 (4%) participants. Prevalence was higher for females 4.6% vs. 3.3% for males, and among younger population for both sex groups. Overall, prevalence of Long COVID by age group was: 18-34 (6%), 35-49 (4.7%), 50-64 (3.4%), ≥65 (1.8%). This is a first estimation of Long COVID prevalence among the French population. Representativeness of the sample should be interpreted with caution due to a sample based on volunteers’ response. Ongoing analyses will provide clearer understanding of the impact of Long COVID. KEY MESSAGES: • This is a first estimation of Long COVID prevalence among the French population. • There is a significant portion of the French population impacted by persisting or reoccurring symptoms defined by Long COVID; its impact and care management will be further evaluated. Oxford University Press 2022-10-25 /pmc/articles/PMC9593843/ http://dx.doi.org/10.1093/eurpub/ckac129.282 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Parallel Programme
Makovski, TT
Decio, V
Carcaillon-Bentata, L
Alleaume, C
Beltzer, N
Robineau, O
Gallay, A
Tebeka, S
Coste, J
Long COVID in France: prevalence, management and long-term impact: Tatjana Makovski
title Long COVID in France: prevalence, management and long-term impact: Tatjana Makovski
title_full Long COVID in France: prevalence, management and long-term impact: Tatjana Makovski
title_fullStr Long COVID in France: prevalence, management and long-term impact: Tatjana Makovski
title_full_unstemmed Long COVID in France: prevalence, management and long-term impact: Tatjana Makovski
title_short Long COVID in France: prevalence, management and long-term impact: Tatjana Makovski
title_sort long covid in france: prevalence, management and long-term impact: tatjana makovski
topic Parallel Programme
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593843/
http://dx.doi.org/10.1093/eurpub/ckac129.282
work_keys_str_mv AT makovskitt longcovidinfranceprevalencemanagementandlongtermimpacttatjanamakovski
AT deciov longcovidinfranceprevalencemanagementandlongtermimpacttatjanamakovski
AT carcaillonbentatal longcovidinfranceprevalencemanagementandlongtermimpacttatjanamakovski
AT alleaumec longcovidinfranceprevalencemanagementandlongtermimpacttatjanamakovski
AT beltzern longcovidinfranceprevalencemanagementandlongtermimpacttatjanamakovski
AT robineauo longcovidinfranceprevalencemanagementandlongtermimpacttatjanamakovski
AT gallaya longcovidinfranceprevalencemanagementandlongtermimpacttatjanamakovski
AT tebekas longcovidinfranceprevalencemanagementandlongtermimpacttatjanamakovski
AT costej longcovidinfranceprevalencemanagementandlongtermimpacttatjanamakovski